Optimization of a yellow fluorescent protein-based iodide influx high-throughput screening assay for cystic fibrosis transmembrane conductance regulator (CFTR) modulators

Assay and Drug Development Technologies

Volumn 8, Issue 6, 2010, Pages 656-668

  Sui, Jinliang ^a,b   Cotard, Shakira ^a   Andersen, Jennifer ^a   Zhu, Ping ^a   Staunton, Jane ^a   Lee, Margaret ^a   Lin, Stephen ^a  

^a Zalicus Inc   (United States)

^b CFRx LLC   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

1 (3 CHLOROPHENYL) 5 TRIFLUOROMETHYL 3 HYDROBENZIMIDAZOL 2 ONE; 1 (5 CHLORO 2 HYDROXY PHENYL) 5 TRIFLUOROMETHYL 1,3 DIHYDROBENZOIMIDAZOL 2 ONE; 2 (2 CHLORO BENZOYLAMINO) 4,5,6,7 TETRAHYDRO BENZO[B]THIOPHENE 3 CARBOXYLIC ACID AMIDE; 2 [(2 1H INDOL 3 YL ACETYL) METHYL AMINO] N (4 ISOPROPYL PHENYL) 2 PHENYL ACETAMIDE; 2 [1 [4 (4 CHLORO BENZENSULFONYL) PIPERAZIN 1 YL] ETHYL] 4 PIPERIDIN 1 YL QUINAZOLINE; 3 (2 BENZYLOXY PHENYL) 5 CHLOROMETHYL ISOXAZOLE; 3 BUT 3 YNYL 5 METHOXY 1 PHENYL 1H PYRAZOLE 4 CARBALDEHYDE; 4 (4 OXO 4H BENZO[H]CHROMEN 2 YL) PYRIDINIUM; 4 [4 OXO 2 THIOXO 3 [3 TRIFLUOROMETHYL PHENYL) THIAZOLIDIN 5 YLIDENE METHYL]BENZOIC ACID; 4 CYCLOHEXYLOXY 2 [1 [4 (4 METHOXY BENZENSULFONYL) PIPERAZIN 1 YL] ETHYL]QUINAZOLINE; 4 METHYL 2 (5 PHENYL 1H PYRAZOL 3 YL) PHENOL; 5,7 DIHYDROXY 3 (4 HYDROXY PHENYL) CHROMAN 4 ONE; 6 (1H BENZOMIDAZOL 2 YLSULFANYLMETHYL) 2 (6 METHOXY 4 METHYL QUINAZOLIN 2 YLAMINO) PYRIMIDIN 4 OL; 6 (ETHYL PHENYL SULFONYL) 4 OXO 1,4 DIHYDRO QUINOLINE 3 CARBOXYLIC ACID 2 METHOXY BENZYLAMIDE; IODIDE; ION TRANSPORT AFFECTING AGENT; N [2 (5 CHLORO 2 METHOXY PHENYLAMINO) 4' METHYL [4,5']BITHIAZOLYL 2' YL] BENZAMIDE; TRANSMEMBRANE CONDUCTANCE REGULATOR; UNCLASSIFIED DRUG; YELLOW FLUORESCENT PROTEIN;

ANIMAL CELL; ARTICLE; CYSTIC FIBROSIS; DRUG ANTAGONISM; DRUG POTENTIATION; GENE DELETION; HIGH THROUGHPUT SCREENING; IN VITRO STUDY; NONHUMAN; RAT;

ANIMALS; CELL LINE; CELLS, CULTURED; CYSTIC FIBROSIS; CYSTIC FIBROSIS TRANSMEMBRANE CONDUCTANCE REGULATOR; HIGH-THROUGHPUT SCREENING ASSAYS; HUMANS; IODIDES; LUMINESCENT MEASUREMENTS; LUMINESCENT PROTEINS; MUTATION; PROTEIN TRANSPORT; RATS;

EID: 78650463149     PISSN: 1540658X     EISSN: None     Source Type: Journal    
DOI: 10.1089/adt.2010.0312     Document Type: Article

References (39)

1. Rommens JM, lannuzzi MC, Kerem B, et al:. Identification of the cystic fibrosis gene: chromosome walking and jumping. Science 1989;245:1059-1065. (Pubitemid 19231813)
2. Ren CL: Cystic fibrosis: evolution from a fatal disease of infancy with a clear phenotype to a chronic disease of adulthood with diverse manifestations. Clin Rev Allergy Immunol Dec 2008;35:97-99.
3. Mulherin D, FitzGerald M: Cystic fibrosis in adolescents and adults. The coming of age of cystic fibrosis. Dig Dis 1992;10:29-37.
4. Pilewski JM, Frizzell RA: Role of CFTR in airway disease. Physiol Rev 1999;79 (1 Suppl):S215-S255.
5. Sheppard DN, Welsh MJ: Structure and function of the CFTR chloride channel. Physiol Rev 1999;79(1 Suppl):S23-S45.
6. Dawson DC, Smith SS, Mansoura MK: CFTR: mechanism of anion conduction. Physiol Rev 1999;79(1 Suppl):S47-S75.
7. Gadsby DC, Vergani P, Csanady L: The ABC protein turned chloride channel whose failure causes cystic fibrosis. Nature 2006;440:477-483.
8. Vergani P, Lockless SW, Nairn AC, Gadsby DC: CFTR channel opening by ATP-driven tight dimerization of its nucleotide-binding domains. Nature 2005; 433:876-880.
9. Zielenski J, Tsui LC: Cystic fibrosis: genotypic and phenotypic variations. Annu Rev Genet 1995;29:777-807.
10. Bobadilla JL, Macek M, Jr., Fine JP, Farrell PM: Cystic fibrosis: a worldwide analysis of CFTR mutations-correlation with incidence data and application to screening. Hum Mutat 2002;19:575-606.
11. Kerem B, Rommens JM, Buchanan JA, et al.: Identification of the cystic fibrosis gene: genetic analysis. Science 1989;245:1073-1080. (Pubitemid 19231815)
12. Baukrowitz T, Hwang TC, Nairn AC, Gadsby DC: Coupling of CFTR Cl- channel gating to an ATP hydrolysis cycle. Neuron 1994;12:473-482.
13. Gadsby DC, Nairn AC: Control of CFTR channel gating by phosphorylation and nucleotide hydrolysis. Physiol Rev 1999;79(1 Suppl):S77-S107.
14. Galietta LJ, Moran O: Identification of CFTR activators and inhibitors: chance or design? Curr Opin Pharmacol 2004;4:497-503.
15. Van Goor F, Straley KS, Cao D, et al.: Rescue of DeltaF508-CFTR trafficking and gating in human cystic fibrosis airway primary cultures by small molecules. Am J Physiol Lung Cell Mol Physiol 2006;290:L1117-L1130.
16. Caci E, Folli C, Zegarra-Moran O, et al.: CFTR activation in human bronchial epithelial cells by novel benzoflavone and benzimidazolone compounds. Am J Physiol Lung Cell Mol Physiol 2003;285:L180-L188.
17. Galietta LJ, Springsteel MF, Eda M, etal.: Novel CFTR chloride channel activators identified by screening of combinatorial libraries based on flavone and benzoquinolizinium lead compounds. J Biol Chem 2001;276:19723-19728.
18. Pedemonte N, Boido D, Moran O, et al.: Structure-activity relationship of 1,4-dihydropyridines as potentiators of the cystic fibrosis transmembrane conductance regulator chloride channel. Mol Pharmacol 2007;72:197-207.
19. Pedemonte N, Diena T, Caci E, et al.: Antihypertensive 1,4-dihydropyridines as correctors of the cystic fibrosis transmembrane conductance regulator channel gating defect caused by cystic fibrosis mutations. Mol Pharmacol 2005;68: 1736-1746. (Pubitemid 41654357)
20. Pedemonte N, Lukacs GL, Du K, et al.: Small-molecule correctors of defective DeltaF508-CFTR cellular processing identified by high-throughput screening. J Clin Invest 2005;115:2564-2571.
21. Pedemonte N, Sonawane ND, Taddei A, et al.: Phenylglycine and sulfonamide correctors of defective delta F508 and G551D cystic fibrosis transmembrane conductance regulator chloride-channel gating. Mol Pharmacol 2005;67:1797-1807.
22. Galietta LJ, Haggie PM, Verkman AS: Green fluorescent protein-based halide indicators with improved chloride and iodide affinities. FEBS Lett 2001;499:220-224.
23. Galietta LV, Jayaraman S, Verkman AS: Cell-based assay for high-throughput quantitative screening of CFTR chloride transport agonists. Am J Physiol Cell Physiol 2001;281:C1734-C1742.
24. Gupta S, Gomez-Munoz A, Matowe WC, Brindley DN, Ginsberg J: Thyroid-stimulating hormone activates phospholipase D in FRTL-5 thyroid cells via stimulation of protein kinase C. Endocrinology 1995;136:3794-3799.
25. Zhang JH, Chung TD, Oldenburg KR: A simple statistical parameter for use in evaluation and validation of high throughput screening assays. J Biomol Screen 1999;4:67-73.
26. Sui Y, Wu Z: Alternative statistical parameter for high-throughput screening assay quality assessment. J Biomol Screen 2007;12:229-234.
27. Van Goor F, Hadida S, Grootenhuis PD, et al.: Rescue of CF airway epithelial cell function in vitro by a CFTR potentiator, VX-770. Proc Natl Acad Sci USA 2009;106:18825-18830.
28. Ma T, Vetrivel L, Yang H, et al.: High-affinity activators of cystic fibrosis transmembrane conductance regulator (CFTR) chloride conductance identified by high-throughput screening. J Biol Chem 2002;277:37235-37241.
29. Sammelson RE, Ma T, Galietta LJ, Verkman AS, Kurth MJ: 3-(2-Benzyloxyphenyl)isoxazoles and isoxazolines: synthesis and evaluation as CFTR activators. Bioorg Med Chem Lett 2003;13:2509-2512.
30. Springsteel MF, Galietta LJ, Ma T, et al.: Benzoflavone activators of the cystic fibrosis transmembrane conductance regulator: towards a pharmacophore model for the nucleotide-binding domain. Bioorg Med Chem 2003;11:4113-4120.
31. Yang H, Shelat AA, Guy RK, et al.: Nanomolar affinity small molecule correctors of defective Delta F508-CFTR chloride channel gating. J Biol Chem 2003;278: 35079-35085.
32. Loo TW, Bartlett MC, Wang Y, Clarke DM: The chemical chaperone CFcor-325 repairs folding defects in the transmembrane domains of CFTR-processing mutants. Biochem J 2006;395:537-542.
33. Borisy AA, Elliott PJ, Hurst NW, et al.: Systematic discovery of multicomponent therapeutics. Proc Natl Acad Sci USA 2003;100:7977-7982.
34. Lehar J, Zimmermann GR, Krueger AS, et al.: Chemical combination effects predict connectivity in biological systems. Mol Syst Biol 2007;3:80.
35. Zimmermann GR, Lehar J, Keith CT: Multi-target therapeutics: when the whole is greater than the sum of the parts. Drug Discov Today 2007;12:34-42.
36. Chen M, Howe D, Leduc B, KerrS, Williams DA: Identification and characterization of two chloramphenicol glucuronides from the in vitro glucuronidation of chloramphenicol in human liver microsomes. Xenobiotica 2007;37:954-971.
37. Lee MS, Johansen L, Zhang Y, et al.: The novel combination of chlorpromazine and pentamidine exerts synergistic antiproliferative effects through dual mitotic action. Cancer Res 2007;67:11359-11367.
38. Devor DC, Bridges RJ, Pilewski JM: Pharmacological modulation on ion transport across wild-type and DeltaF508 CFTR-expressing human bronchial epithelia. Am J Physiol Cell Physiol 279:C461-C479.
39. Lin S, Sui JL, Cotard S, et al.: Identification of Synergistic combinations of F508del cystic fibrosis transmembrane conductance regulator modulators. Assay Drug Dev Technol 2010;8:669-684.